March 19, 2013 7:22 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Deutsche Bank initiated coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and a $45.00 price target.Deutsche Bank analyst Robyn Karnauskas commented, "Sarepta is developing a RNA modulator, Eteplirsen, for the treatment of Duchenne Muscular Dystrophy (DMD). While our checks indicate Eteplirsen is unlikely to get accelerated approval, we see approval likely by mid-2015. We see Eteplirsen as having better safety profile versus its competitor Drisapersen that will allow it to take majority share. We see fair-value of Eteplirsen in the US only at $45/share & tremendous upside if the street assigns value to EU or other exon therapy opportunities."Sarepta Therapeutics closed at $33.03 on Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.